Merck Says Antiviral Pill for COVID-19 Is Effective, Plans to File for Emergency Authorization The antiviral, molnupiravir, cut the risk of hospitalization or death in half for adults who were deemed at risk but not hospitalized, according to a planned interim analysis of the trial.

By The Epoch Times

This story originally appeared on The Epoch Times

Results from a clinical trial show that Merck's antiviral pill for COVID-19 is effective, the company said Friday.

The antiviral, molnupiravir, cut the risk of hospitalization or death in half for adults who were deemed at risk but not hospitalized, according to a planned interim analysis of the trial.

Compared to the 14.1 percent of patients who received placebos, 7.3 percent of trial participants who received the drug were hospitalized through day 29, the company and its partner Ridgeback Biotherapeutics said.

Eight people died in the placebo group and zero did in the group given molnupiravir.

Based on the findings, Merck plans to apply to the Food and Drug Administration (FDA) soon for emergency use authorization for its drug.

"With these compelling results, we are optimistic that molnupiravir can become an important medicine as part of the global effort to fight the pandemic," Robert Davis, Merck's CEO and president, said in a statement.

"We are very encouraged by the results from the interim analysis and hope molnupiravir, if authorized for use, can make a profound impact in controlling the pandemic," added Wendy Holman, the CEO of Ridgeback.

The drug works by inhibiting the replication of the virus that causes COVID-19. The virus is known as SARS-CoV-2 or the CCP (Chinese Communist Party) virus. So far, the only drugs authorized to treat COVID-19 are monoclonal antibodies, which run over $2,000 each and take more time to administer than a pill. However, clinical trials on drugs approved for other uses, including the antidepressant fluvoxamine, have shown promise against the disease.

The molnupiravir trial analysis evaluated data from 775 patients who had laboratory-confirmed cases of COVID-19. None had received a COVID-19 vaccine. The phase 3 trial was meant to enroll 1,550 patients, but enrollment was stopped at the recommendation of a Data Monitoring Committee in consultation with the FDA. The trial was conducted at sites around the world, including in the United States. Full results have not yet been released. Merck did not immediately respond to emailed questions.

The company did say that the analysis found an incidence of adverse events comparable between the groups, with 35 percent of participants getting its drug experiencing an event and 40 percent of the placebo group experiencing an event. The incidence of adverse events described as being related to the drug was similar between the groups.

Merck has already been producing doses of molnupiravir in anticipation of the results from the trial and projects to produce 10 million courses by the end of the year. The United States earlier this year agreed to buy approximately 1.7 million doses upon emergency authorization or approval from U.S. drug regulators. Each course, which involves multiple pills, will cost the government $705 if the agreement kicks in.

Dr. Walid Gellad, professor of medicine at the University of Pittsburg's School of Medicine, said the antiviral would be "a game changer" and urged the FDA to prioritize granting it authorization.

Other experts noted that the data has not been peer reviewed but said the results appeared encouraging.

Two other companies are also racing to develop antiviral pills against COVID-19.

Pfizer launched two trials of its oral drug last month while Roche is also studying its version.

By Zachary Stieber

Zachary Stieber covers U.S. news, including politics and court cases. He started at The Epoch Times as a New York City metro reporter.

The Epoch Times, founded in 2000, is headquartered in Manhattan, New York, with a mission to provide independent and accurate information free of political bias or corporate influence. The organization was established in response to censorship within China and a lack of global awareness regarding the Chinese regime's repression of the spiritual practice Falun Gong.

The Epoch Times is a widely read newspaper that is distributed in 33 countries and is available in 21 languages. The publication has been critical in providing balanced and detailed reporting on major global events such as the 2003 SARS pandemic and the 2008 financial crisis. Notably, the organization has played a key role in exposing corruption inside China.

Aside from its human rights coverage, The Epoch Times has made significant contributions in a variety of fields. It has received praise for its in-depth analysis and expert perspectives on business, the economy and U.S. politics. The newspaper has also received praise for its broad coverage of these topics.

A series of editorials titled "Nine Commentaries on the Communist Party" appeared in The Epoch Times in 2004. It asserts that freedom and prosperity in China can only be achieved by eliminating the Communist Party, which violated China's cultural and spiritual values. In addition, the organization led the Tuidang movement, which resulted in over 400 million Chinese citizens quitting the Communist Party. In spite of this, 90% of websites referring to the "Nine Commentaries" were blocked by the Chinese regime.

The Epoch Times has been at the forefront of investigating high-level corruption cases within the Chinese regime, with its reporters taking significant risks to uncover these stories. The organization has received several awards for its investigative journalism.

The organization has received several awards for its investigative journalism. For more, visit

Editor's Pick

Related Topics

Side Hustle

Anyone Can Start a Passive Income Side Hustle For Easy Money — But Only If You Know These 5 Essential Tips First.

The rise of digital automation technology has made starting a passive income side hustle easier and more accessible than ever before.

Business News

An Hermès Heir Wants to Give Half His $12 Billion Fortune to His Gardener—and Lawyers Are Going Nuts

Nicolas Puech, the grandson of Hermès' founder, intends to legally adopt the 51-year-old former groundskeeper as his son, ensuring he inherits his billions.

Side Hustle

He Launched His Creative Side Hustle Out of a Garage. Now It's Worth $225 Million.

Tom Humble, CXO and founder of E.C.D. Automotive Design, followed his passion for custom auto design into big business.


How to Start a 'Million Dollar' Morning Routine

Restructure your morning with a few simple steps that may help to amplify your energy.

Business Ideas

55 Small Business Ideas to Start in 2023

We put together a list of the best, most profitable small business ideas for entrepreneurs to pursue in 2023.